ROCKVILLE, MD / ACCESS Newswire / October 2, 2026 / American Gene Technologies ("AGT"), a clinical-stage biotech developing AGT103-T - the only program to demonstrate elimination of the HIV viral reservoir in humans - will present at the National Investment Banking Association (NIBA) 153rd Investment Conference on October 6-7, 2026.

AGT is raising $55 million to fund its Phase 2 trial of this one-time, gene-modified T-cell therapy targeting a functional cure for HIV in a $40 billion annual market. Backed by a successful Phase 1 trial, FDA Fast Track designation, 60+ patents.

AGT will be available for one-on-one investor meetings on October 7. To schedule a meeting, contact Drew Palin, President, at wdpalin@americangene.com or visit nibanet.org for details.

SOURCE: American Gene Technologies